GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PB-119

Company
PegBio Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02084251

    Clinical Trial for PB-119 in Healthy Subjects (Phase I)

    Not yet reported PegBio Co., Ltd. 70 participants Est. completion 2014-11 1 site Added to GLP-1
    Other conditions: Type II Diabetes
    View official trial listing →
  • Completed NCT NCT03059719

    Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

    Not yet reported PegBio Co., Ltd. 36 participants Est. completion 2016-10-27 1 site Stand-alone
    Other conditions: Type II Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03062774

    Continuous Multiple Dose PB-119 Injection in Health Volunteers

    Not yet reported PegBio Co., Ltd. 36 participants Est. completion 2016-10-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03072407

    MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

    Not yet reported PegBio Co., Ltd. 40 participants Est. completion 2016-11-15 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03520972

    Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

    Not yet reported PegBio Co., Ltd. 251 participants Est. completion 2019-07-29 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03604419

    Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

    Not yet reported PegBio Co., Ltd. 214 participants Est. completion 2019-07-23 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04504370

    Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

    Not yet reported PegBio Co., Ltd. 273 participants Est. completion 2022-11-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04504396

    Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy

    Not yet reported PegBio Co., Ltd. 620 participants Est. completion 2023-05-26 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT05328843

    Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function

    Not yet reported PegBio Co., Ltd. 24 participants Est. completion 2022-10-01 1 site Stand-alone
    Other conditions: Type2Diabetes
    View official trial listing →
  • Completed NCT NCT06350812

    A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

    Not yet reported, Not yet reported PegBio Co., Ltd. 32 participants Est. completion 2024-12-16 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.